Edwin Rock, Chief Medical Officer at GlycoMimetics (NASDAQ:GLYC), reported a large insider buy on September 25, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Rock purchased 65,403 shares of GlycoMimetics. The total transaction amounted to $90,256.
GlycoMimetics shares are trading up 7.75% at $1.39 at the time of this writing on Tuesday morning.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
The Importance of Insider Transactions
Insider transactions shouldn't be used primarily to make an investing decision, however, they ...